Ranok has developed CHAMP (Chaperone-mediated Protein Degradation), a proprietary targeted protein degradation (TPD) platform that leverages the cellular chaperome network to selectively target disease tissues. The company positions CHAMP as differentiated from other degrader approaches such as PROTAC, with potential advantages in safety and efficacy. Ranok’s leadership includes industry veterans with deep experience in protein homeostasis and drug discovery. The company is advancing a most-advanced cancer program toward clinical trials in the near future and plans to expand its preclinical pipeline of CHAMP-based therapies. Ranok is based in Hangzhou, China and Greater Boston, Massachusetts, and intends to use new funding to accelerate R&D and candidate advancement. Financially, the company has disclosed a $40 million Series B and stated it has raised the equivalent of over $50 million to date.

Total raised

$40M

Funding rounds

1

Latest round

Series B

Latest activity

Aug 2021